Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BT makes 'solid start' to FY25, H1 adjusted revenues down 3pc

(Sharecast News) - Telecommunications giant BT said on Thursday that it has made "a solid start to the year" despite seeing both revenues and profits decline. BT said total adjusted revenues slipped 3% year-on-year to £4.87bn, mainly due to weaker handset sales and "continued challenging international trading", and adjusted earnings dipped by 1% to £2.05bn.

Reported pre-tax profits were 10% lower at £468.0m, primarily due to an increase in net finance costs and depreciation and amortisation.

However, despite the modest H1 declines on both the top and bottom lines, BT said it remained on track to achieve its FY26 and multi-year financial guidance.

On the operational front, BT reported "record customer demand" for Openreach FTTP, with net adds up 46% year-on-year to 566,000, while its retail FTTP base grew by 32% to 3.7m and its total customer base increased in the period, with its broadband base up 11,000 and post-paid mobile base up 41,000.

However, Openreach broadband lines fell by 169,000, driven by losses to competitors and a weaker broadband market, and business adjusted UK service revenue was down 2%.

Separately, the FTSE 100-listed group announced that chief financial officer Simon Lowth plans to retire from the group. Lowth will be succeeded by Patricia Cobian, who will join BT in summer 2026, and will eventually retire following a managed handover.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.